Active — Not RecruitingPhase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

China13 participantsStarted 2025-08-07

Plain-language summary

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Currently enrolled and active in the originator study, JZNJ. A participant is considered active in the study if they are receiving study intervention * Agree to comply with contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Exclusion Criteria: * Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment

What they're measuring

Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events

Timeframe: Day 1 through 28 days after last dose or start of new anticancer therapy

Trial details

NCT IDNCT07162181

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2030-05

View on ClinicalTrials.gov More Lymphoma, Non-Hodgkin trials